Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study.
Saved in:
| Title: | Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study. |
|---|---|
| Authors: | Bae S; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea., Lee H; Department of Health Science and Technology, Seoul National University College of Convergence Science and Technology, Seongnam, Republic of Korea.; Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Dolmaro 172, Seongnam, Gyeongi, 13605, Republic of Korea., Song I; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea., Kim J; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea., Lee SR; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea., Cho S; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea., Yu KS; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea., Chung JY; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. jychung@snubh.org.; Department of Health Science and Technology, Seoul National University College of Convergence Science and Technology, Seongnam, Republic of Korea. jychung@snubh.org.; Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Dolmaro 172, Seongnam, Gyeongi, 13605, Republic of Korea. jychung@snubh.org. |
| Source: | CNS drugs [CNS Drugs] 2025 Jun; Vol. 39 (6), pp. 583-595. Date of Electronic Publication: 2025 Apr 15. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9431220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1934 (Electronic) Linking ISSN: 11727047 NLM ISO Abbreviation: CNS Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1179-1934 |
|---|---|
| DOI: | 10.1007/s40263-025-01181-9 |
